2 citations
,
September 2019 Alopecia areata treatments should be personalized, using options like steroids, JAK inhibitors, and other therapies based on individual needs.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
63 citations
,
April 1985 in “Journal of the American Academy of Dermatology” Topical PUVA can cause temporary hair regrowth in some alopecia areata patients but doesn't change the long-term outcome.
December 2012 in “http://isrctn.org/>” 29 citations
,
March 2023 in “The Journal of Dermatology” Dupilumab for atopic dermatitis can cause mild skin issues in some patients.
49 citations
,
April 2000 in “Journal of The American Academy of Dermatology” Despite progress in treatment, the exact cause of Alopecia areata is still unknown.
November 2023 in “Journal of Investigative Dermatology” The study identified key immune cell differences between mild and severe alopecia areata.
January 2024 in “Biomedicines” The review shows that skin symptoms like chronic fungal infections, hair loss, and skin depigmentation are key for early detection and management of APECED.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
6 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
May 2015 in “Journal of The American Academy of Dermatology” Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.
20 citations
,
August 2021 in “Clinical and Experimental Dermatology” A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.
August 2025 in “Kuban Scientific Medical Bulletin” Personalized treatment considering atopic status and cytokine profiles may help in managing pediatric alopecia areata.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
33 citations
,
June 2021 in “Dermatologic Therapy” COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
26 citations
,
September 2009 in “Clinical genetics” Arab APS1 patients have unique and recurrent AIRE gene mutations.
26 citations
,
July 2019 in “JAAD Case Reports” Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
October 2022 in “Dermatologic Therapy” Both treatments for resistant alopecia areata were equally effective.
January 2007 in “Elsevier eBooks” Alopecia areata is a reversible, autoimmune-related hair loss that can have significant emotional impact and uncertain treatment effectiveness.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
February 2026 in “Journal of Drugs in Dermatology” Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
5 citations
,
April 2013 in “Nasza Dermatologia Online” Oral zinc therapy is effective for treating acrodermatitis enteropathica.
January 2025 in “ACS Applied Materials & Interfaces” Nanoparticles with specific drugs can help regrow hair in alopecia areata.
15 citations
,
May 1999 in “Journal of Investigative Dermatology” Alopecia areata is complex, with genetic and immune factors, and animal models are key for future treatment research.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
2 citations
,
October 2000 in “Journal of Investigative Dermatology” AUC and APL are distinct conditions needing careful clinical assessment.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
The treatment showed promising results in improving advanced-stage hair loss.